In the COVID-19 era, pharmaceutical companies are fast learning that digital transformation strategy is not just an appealing concept but a strategic imperative. With the pandemic offering an unexpected template for agile means of remote working, multinationals such as Pfizer have embraced digital technologies as catalysts for change at every level of their organisation.
Topics: launch planning, #covid-19, digital transformation
The COVID-19 pandemic is a wake-up call for the pharmaceutical industry to embed digital transformation at every level of its operations. That includes market access, tendering and pharma product launch activities.
Topics: launch planning, #covid-19, digital transformation
The widespread disruption caused by the coronavirus pandemic is forcing pharmaceutical companies to think more creatively and flexibly about how their business model can accommodate new restraints such as home working, restricted face-to-face contact, travel bans, supply-chain bottlenecks, stalled clinical-trial recruitment, diverted healthcare budgets, closer scrutiny of drug reimbursement, and depleted staffing at regulatory agencies. Digital technology will be a crucial tool in addressing these challenges and softening the pandemic’s multiple potential impacts on drug launches.
Topics: Pharma launch planning, Pharma trends, Market access, launch readiness, Tender Management, #covid-19, coronavirus
Certificate No. 345262020